Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin

The Lancet

Volumn 339, Issue 8803, 1992, Pages 1195-1196

  Falini, B ^a   Flenghi, L ^a   Aversa, F ^a   Barbabietola, G ^a   Martelli, M F ^a   Comeli, P ^a   Tazzari, P L ^b   Broe, M K ^c   Stein, H ^d   Dürkop, H ^d   Pizzolo, G ^e   Bolognesi, A ^f   Stirpe, F ^f   Sabattini, E ^f   Pileri, S ^f  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c Research and Development   (Denmark)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

^e UNIVERSITY OF VERONA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; IMMUNOTOXIN; MONOCLONAL ANTIBODY; SAPORIN;

ANTIBODY RESPONSE; ARTICLE; CASE REPORT; DRUG RESPONSE; HODGKIN DISEASE; HUMAN; IMMUNOHISTOLOGY; PRIORITY JOURNAL;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD30; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HODGKIN DISEASE; HUMAN; IMMUNOTOXINS; PLANT PROTEINS; SUPPORT, NON-U.S. GOV'T;

EID: 0026587530     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(92)91135-U     Document Type: Article

References (10)

1. Ber-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope
2. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Stemberg and histiocytic malignancies are derived from activated lymphoid cells
3. In vivo targeting of Hodgkin and Reed-Stemberg cells of Hodgkin's disease with monoclonal antibody Ber-H2 (CD30)
4. Evaluation of ricin A chain-containing immunotoxms directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease
5. Anti-tumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice
6. Ribosome-inactivating proteins up to date
7. Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage
8. Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein from Saponaria officinalis
9. Phase I immunotoxin trial in patients with B-cell lymphomas